Orexo´s product portfolio contains of traditional pharma products and digital therapies. These products have been developed with a focus on innovative solutions to address patient need, mostly within mental diseases, such as substance use disorder and depression. The products are commercialized in the US by Orexo and through partners worldwide. 








Opioid use disorder

Breakthrough cancer pain

Sleeping problems

Symptoms of mild to severe depression

Heavy alcohol use, incl. alcohol use
disorder (AUD)


Orexo is seeking partners for markets ex.US

In-licensed from 

In-licensed from 

Commercial rights

Orexo worldwide, except for Australia and New Zealand where Mundipharma Pty Ltd. owns the rights 

Kyowa Kirin worldwide ex the EU and the US

Mylan worldwide

Orexo owns the exclusive rights to the US market

Orexo owns the exclusive rights to the US market